Compare Biocon with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PIRAMAL ENTERPRISES BIOCON /
PIRAMAL ENTERPRISES
 
P/E (TTM) x 33.6 -42.1 - View Chart
P/BV x 4.0 1.4 282.1% View Chart
Dividend Yield % 0.2 1.6 15.1%  

Financials

 BIOCON    PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON
Mar-19
PIRAMAL ENTERPRISES
Mar-19
BIOCON /
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7073,303 21.4%   
Low Rs5541,797 30.8%   
Sales per share (Unadj.) Rs91.9716.5 12.8%  
Earnings per share (Unadj.) Rs16.779.7 21.0%  
Cash flow per share (Unadj.) Rs24.2107.9 22.4%  
Dividends per share (Unadj.) Rs1.0028.00 3.6%  
Dividend yield (eoy) %0.21.1 14.4%  
Book value per share (Unadj.) Rs101.61,477.5 6.9%  
Shares outstanding (eoy) m600.00184.45 325.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.93.6 192.8%   
Avg P/E ratio x37.732.0 118.0%  
P/CF ratio (eoy) x26.123.6 110.4%  
Price / Book Value ratio x6.21.7 359.5%  
Dividend payout %6.035.1 17.0%   
Avg Mkt Cap Rs m378,330470,292 80.4%   
No. of employees `0006.17.8 78.4%   
Total wages/salary Rs m11,65322,504 51.8%   
Avg. sales/employee Rs Th8,994.316,899.4 53.2%   
Avg. wages/employee Rs Th1,900.72,877.7 66.0%   
Avg. net profit/employee Rs Th1,635.31,879.9 87.0%   
INCOME DATA
Net Sales Rs m55,144132,153 41.7%  
Other income Rs m1,4443,128 46.2%   
Total revenues Rs m56,588135,281 41.8%   
Gross profit Rs m15,88366,290 24.0%  
Depreciation Rs m4,4785,202 86.1%   
Interest Rs m70944,097 1.6%   
Profit before tax Rs m12,14020,119 60.3%   
Minority Interest Rs m93,194 0.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1238,611 24.7%   
Profit after tax Rs m10,02614,701 68.2%  
Gross profit margin %28.850.2 57.4%  
Effective tax rate %17.542.8 40.9%   
Net profit margin %18.211.1 163.4%  
BALANCE SHEET DATA
Current assets Rs m48,228122,742 39.3%   
Current liabilities Rs m30,376310,810 9.8%   
Net working cap to sales %32.4-142.3 -22.7%  
Current ratio x1.60.4 402.0%  
Inventory Days Days6823 296.0%  
Debtors Days Days8639 220.1%  
Net fixed assets Rs m64,130116,904 54.9%   
Share capital Rs m3,000369 813.2%   
"Free" reserves Rs m57,980272,161 21.3%   
Net worth Rs m60,980272,530 22.4%   
Long term debt Rs m15,766270,196 5.8%   
Total assets Rs m121,924856,261 14.2%  
Interest coverage x18.11.5 1,244.5%   
Debt to equity ratio x0.31.0 26.1%  
Sales to assets ratio x0.50.2 293.0%   
Return on assets %8.86.9 128.2%  
Return on equity %16.45.4 304.8%  
Return on capital %16.812.4 134.9%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50615,200 102.0%   
Fx outflow Rs m10,3994,889 212.7%   
Net fx Rs m5,10710,312 49.5%   
CASH FLOW
From Operations Rs m11,546-115,975 -10.0%  
From Investments Rs m-7,138-8,265 86.4%  
From Financial Activity Rs m-2,417107,525 -2.2%  
Net Cashflow Rs m2,103-16,650 -12.6%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SHASUN PHARMA  WYETH  ABBOTT INDIA  ALEMBIC  DR. REDDYS LAB  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

India Top US Crude Oil Buyer in Q1CY21, Adani Ports Removed from S&P Index, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note on Tuesday. Benchmark indices extended gains after the Indian government fast-tracked emergency approvals for foreign produced Covid-19 vaccines.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 13, 2021 (Close)

TRACK BIOCON

BIOCON - CADILA HEALTHCARE COMPARISON

COMPARE BIOCON WITH

MARKET STATS